Daratumumab
- Generic Name
- Daratumumab
- Brand Names
- Darzalex, Darzalex Faspro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 945721-28-8
- Unique Ingredient Identifier
- 4Z63YK6E0E
- Background
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.
...
- Indication
Daratumumab is indicated as an intravenous injection alone or in combination with other medications for the treatment of multiple myeloma. It is available as a combination product with hyaluronidase for the treatment of adults with multiple myeloma as monotherapy or combination therapy and light chain amyloidosis in combination with other drugs.
- Associated Conditions
- Multiple Myeloma (MM), Primary Amyloidosis, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-05-01
- Target Recruit Count
- 188
- Registration Number
- NCT05835726
- Locations
- 🇮🇹
Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy
Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients With Aplastic Anemia
- Conditions
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-04-27
- Target Recruit Count
- 10
- Registration Number
- NCT05832216
- Locations
- 🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China
Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Istituto Giannina Gaslini
- Target Recruit Count
- 20
- Registration Number
- NCT05704400
- Locations
- 🇮🇹
IRCCS G. Gaslini, Genova, Italy
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
- Conditions
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- University of Heidelberg Medical Center
- Target Recruit Count
- 130
- Registration Number
- NCT05695508
- Locations
- 🇩🇪
Charité University Medicin Berlin, Berlin, Germany
🇩🇪Clinic Chemnitz gGmbH, Chemnitz, Germany
🇩🇪University Clinic Technical University Dresden, Dresden, Germany
Daratumumab in Primary Antiphospholipid Syndrome
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-11-29
- Target Recruit Count
- 22
- Registration Number
- NCT05671757
- Locations
- 🇺🇸
NYU Langone, New York, New York, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
- Conditions
- Interventions
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 40
- Registration Number
- NCT05654506
- Locations
- 🇺🇸
Mayo Clinic Minnesota, Rochester, Minnesota, United States
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Anaveon AG
- Target Recruit Count
- 4
- Registration Number
- NCT05641324
- Locations
- 🇩🇰
Vejle Hospital, Vejle, Denmark
🇫🇷CHU de Nantes - Hôtel-Dieu, Nantes, France
🇫🇷Institut Paoli-Calmettes, Marseille, France
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, Lenalidomide or Elranatamab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Conditions
- Interventions
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1116
- Registration Number
- NCT05623020
- Locations
- 🇮🇹
ASL PESCARA-Presidio Ospedaliero Pescara, Pescara, Italy
🇮🇹AOU Policlinico Umberto I, Roma, Italy
🇦🇺Pindara Private Hospital, Benowa, Queensland, Australia
A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 58
- Registration Number
- NCT05590377
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸HCA Midwest Health (Midwest Ventures Group HCA MidAmerica Division), Overland Park, Kansas, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne, Indiana, United States
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 48
- Registration Number
- NCT05581875
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.